Literature DB >> 21095546

Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Barbara Zarebczan1, Herbert Chen.   

Abstract

Although neuroendocrine tumors are rare, the more common types such as gastrointestinal and pancreatic carcinoids, medullary thyroid cancers, and small cell lung cancers have been studied in detail during the last few years. Data published thus far indicate that multiple signaling pathways are involved in these cancers. Recent focus has been on developing novel therapeutics by targeting specific signaling pathways. This article details several of the signaling mechanisms that have been discovered to play a role in the development and progression of neuroendocrine tumors. The therapeutic options developed to address the various pathways, including their specific mechanisms of actions, are also discussed.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21095546      PMCID: PMC3011942          DOI: 10.1016/j.ecl.2010.08.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  58 in total

Review 1.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

Review 2.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

Review 3.  Notch signaling: the demise of elegant simplicity.

Authors:  Tom Kadesch
Journal:  Curr Opin Genet Dev       Date:  2004-10       Impact factor: 5.578

Review 4.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  B Zarebczan; H Chen
Journal:  Minerva Chir       Date:  2010-02       Impact factor: 1.000

Review 5.  Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.

Authors:  Anastasios T Dimou; Konstantinos N Syrigos; Muhammad Wasif Saif
Journal:  JOP       Date:  2010-03-05

6.  The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors.

Authors:  N Younes; N Fulton; R Tanaka; J Wayne; F H Straus; E L Kaplan
Journal:  Cancer       Date:  1997-05-01       Impact factor: 6.860

7.  Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells.

Authors:  Rebecca S Sippel; Jennifer E Carpenter; Muthusamy Kunnimalaiyaan; Sara Lagerholm; Herbert Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-08       Impact factor: 4.052

8.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

Review 9.  Medullary thyroid cancer: molecular biology and novel molecular therapies.

Authors:  Mehtap Cakir; Ashley B Grossman
Journal:  Neuroendocrinology       Date:  2009-05-25       Impact factor: 4.914

10.  TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.

Authors:  L W Ellisen; J Bird; D C West; A L Soreng; T C Reynolds; S D Smith; J Sklar
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

View more
  8 in total

1.  Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Amit Tirosh; Sanjit Mukherjee; Justin Lack; Sudheer Kumar Gara; Sophie Wang; Martha M Quezado; Xavier M Keutgen; Xiaolin Wu; Maggie Cam; Suresh Kumar; Dhaval Patel; Naris Nilubol; Monica Varun Tyagi; Electron Kebebew
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

Review 2.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

Review 3.  Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.

Authors:  Krystallenia I Alexandraki; Gregory Kaltsas
Journal:  Endocrine       Date:  2011-11-29       Impact factor: 3.633

Review 4.  Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Authors:  Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2021-10-12       Impact factor: 6.639

5.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

6.  Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.

Authors:  Sara Tesfazghi; Jacob Eide; Ajitha Dammalapati; Colin Korlesky; Thomas P Wyche; Tim S Bugni; Herbert Chen; Renata Jaskula-Sztul
Journal:  Cancer Med       Date:  2013-09-17       Impact factor: 4.452

Review 7.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335

Review 8.  The Role of Notch Signaling and Leptin-Notch Crosstalk in Pancreatic Cancer.

Authors:  Adriana Harbuzariu; Gabriela M Oprea-Ilies; Ruben R Gonzalez-Perez
Journal:  Medicines (Basel)       Date:  2018-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.